Oxazyme

Oxazyme is an orally administered drug composed of a recombinant mutant form of the enzyme oxalate decarboxylase (C383S) derived from Bacillus subtilis. It is designed to enzymatically degrade dietary oxalate in the gastrointestinal tract before absorption, thereby reducing urinary excretion of oxalate and preventing the formation of calcium-oxalate kidney stones. The drug acts as a dietary intercept therapeutic for secondary hyperoxaluria and recurrent stone disease by breaking down food-borne oxalate in the stomach and intestine. This approach aims to lower blood levels of oxalate and decrease its renal excretion, potentially reducing kidney stone risk and associated complications[1][2][3][5][8]. **Developer:** OxThera

Brand names

Oxazyme

Other names

recombinant Bacillus subtilis oxalate decarboxylaserecombinant oxalate degrading enzymeOxDC C383S mutant